Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Asset Writedowns and Impairment (2024 - 2025)

Foghorn Therapeutics (FHTX) has 1 years of Asset Writedowns and Impairment data on record, last reported at $5.9 million in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $5.9 million; the TTM value through Dec 2025 reached $5.9 million, changed N/A, while the annual FY2025 figure was $5.9 million, 146.04% up from the prior year.
  • Asset Writedowns and Impairment reached $5.9 million in Q4 2025 per FHTX's latest filing.
  • Across five years, Asset Writedowns and Impairment topped out at $5.9 million in Q4 2025 and bottomed at $5.9 million in Q4 2025.